Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ 210 Cr.
- Current Price ₹ 189
- High / Low ₹ 220 / 53.8
- Stock P/E 21.7
- Book Value ₹ 49.2
- Dividend Yield 0.00 %
- ROCE 28.9 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 13.35 | 57.38 | 89.63 | |
| 10.78 | 45.49 | 74.66 | |
| Operating Profit | 2.57 | 11.89 | 14.97 |
| OPM % | 19.25% | 20.72% | 16.70% |
| 0.05 | 0.09 | 0.19 | |
| Interest | 0.40 | 1.44 | 0.87 |
| Depreciation | 0.22 | 0.77 | 1.21 |
| Profit before tax | 2.00 | 9.77 | 13.08 |
| Tax % | 25.00% | 30.40% | 26.15% |
| 1.49 | 6.79 | 9.67 | |
| EPS in Rs | 3.72 | 8.31 | 8.70 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 222% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 28% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 4.00 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 43.59 |
| 13.48 | 14.10 | 12.32 | |
| 8.47 | 10.48 | 9.65 | |
| Total Liabilities | 27.44 | 39.87 | 76.68 |
| 5.25 | 6.09 | 13.21 | |
| CWIP | 0.00 | 0.00 | 0.20 |
| Investments | 0.00 | 0.00 | 0.00 |
| 22.19 | 33.78 | 63.27 | |
| Total Assets | 27.44 | 39.87 | 76.68 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -11.51 | -0.62 | -14.53 | |
| -5.48 | -1.61 | -8.53 | |
| 17.08 | 2.19 | 27.04 | |
| Net Cash Flow | 0.09 | -0.04 | 3.97 |
| Free Cash Flow | -16.99 | -2.23 | -23.06 |
| CFO/OP | -479% | 18% | -75% |
Ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 158.58 | 74.17 | 91.22 |
| Inventory Days | 564.06 | 188.49 | 158.92 |
| Days Payable | 256.32 | 69.41 | 32.32 |
| Cash Conversion Cycle | 466.31 | 193.25 | 217.82 |
| Working Capital Days | 189.47 | 64.69 | 144.73 |
| ROCE % | 46.36% | 28.94% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Capacity Utilization - Capsules % |
|
|||
| Capacity Utilization - External Preparations % |
||||
| Capacity Utilization - Oral Liquid % |
||||
| Capacity Utilization - Oral Powder % |
||||
| Capacity Utilization - Tablets % |
||||
| Direct Export Revenue Share % |
||||
| Sales on Contract Manufacturing / Loan License Revenue Share % |
||||
| Top 10 Customer Revenue Concentration % |
||||
Extracted by Screener AI
Documents
Announcements
-
Amendment to AOA/MOA
- Postal ballot approved 1 Sep 2026 object clause change; MOA amended on 9 Oct 2026.
-
Shareholders meeting
- Postal ballot passed five special resolutions, including MOA alteration, higher borrowing limits, and mortgage/charge creation.
-
Shareholders meeting
- Postal ballot passed 5 special resolutions on MOA alteration, borrowing limits, charges, and subsidiary support.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
- Accretion Pharmaceuticals says Regulation 27(2) corporate governance report not applicable for quarter ended 30 September 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2025
from web
Concalls
-
May 2026PPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.